Paclitaxel: a review of adverse toxicities and novel delivery strategies.

Abstract

Better known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemotherapeutic agent has become a broadly accepted option in the treatment of patients with ovarian, breast and non-small cell lung cancers, malignant brain tumors, and a variety of other solid tumors. However, significant toxicities, such as myelosuppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based treatment regimens. This review addresses the toxicities associated with paclitaxel treatment and describes existing and future strategies of paclitaxel administration directed at limiting these toxicities.

• Authors: Neena I Marupudi, James E Han, Khan W Li, Violette M Renard, Betty M Tyler, Henry Brem
• Journal: Expert opinion on drug safety (Expert Opin Drug Saf) Vol. 6 Issue 5 Pg. 609-21 (Sep 2007) ISSN: 1744-764X [Electronic] England
• PMID: 17877447 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Paclitaxel

Topics

• Animals
• Drug Delivery Systems (methods, trends)
• Humans
• Paclitaxel (administration & dosage, adverse effects, chemistry)